AVDL AVADEL PHARMACEUTICALS PLC Management Changes 8-K Filing 2024 - Management Change Richard Kim, the Chief Commercial Officer of Avadel Pharmaceuticals, will resign effective December 31, 2024, and will receive 2024 incentive compensation as part of his separation agreement.Get access to all SEC 8-K filings of the AVADEL PHARMACEUTICALS PLC